Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1

BIOLOGICAL2 trials

Sponsors

GeoVax, Inc., City of Hope Medical Center

Conditions

COVID-19 InfectionChronic Lymphocytic Leukemia

Phase 1

A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection

CompletedNCT04639466

GeoVax, Inc.COVID-19 Infection

Start: 2020-11-19End: 2025-12-03Updated: 2026-02-10

Phase 2

A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

CompletedNCT05672355

City of Hope Medical CenterChronic Lymphocytic Leukemia, COVID-19 Infection

Start: 2023-08-01End: 2026-07-07Updated: 2026-09-09

Related Papers

First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster

Vaccines2024-11-185 citations

Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial.

2022-03-0941 citations